Sign In

MSc Sten Verland

General Partner - Sunstone Life Science Ventures

Professional Background

Sten Verland D. MSc is an accomplished professional with extensive experience in the life sciences and venture capital sectors. His expertise spans executive management, strategic development, mergers and acquisitions (M&A), entrepreneurship, and both non-clinical and clinical drug development. As a founding partner and General Partner at Sunstone Life Science Ventures, Sten has been at the forefront of the investment landscape in life sciences, leveraging his deep understanding of scientific research and business acumen to identify and nurture promising ventures.

Throughout his illustrious career, Sten has held numerous prestigious positions within various organizations. Notably, he has served as a Non-Executive Director in several biotech firms, including Stipe Therapeutics, OxThera, and Glycom A/S, where his insights have guided innovative drug development and strategic growth initiatives. His role as a Panel Member at The Research Council of Norway and participation in selection committees at Innovation Fund Denmark reflect his commitment to advancing scientific research and fostering entrepreneurship in Denmark.

Sten's professional journey also includes a remarkable history of leadership in both corporate and educational settings. He has held key roles such as CEO & Owner of Verland Capital and VP General Manager Europe at Synarc (now BioClinica). His extensive board experience, notably as Chairman at Action Pharma A/S and Zymenex, underscores his capability to lead complex organizations through critical growth phases.

Education and Achievements

Sten Verland's educational background is rooted in rigorous scientific training. He holds a Doctor of Philosophy (PhD) in Immunology from Københavns Universitet (University of Copenhagen), where he engaged in advanced research that contributed to the field of immunology. His Master of Science (MSc) degree in Biology and Mathematics from the same esteemed institution instilled a strong foundational knowledge that underpins his understanding of the biological sciences and quantitative analysis.

His academic pursuits paved the way for a successful career that merges science with business. During his tenure as an Assistant Professor at the Institute for Experimental Immunology, Medical School, University of Copenhagen, he not only contributed to the academic community but also mentored the next generation of scientists. This blend of academic and industry experience positions him uniquely to understand the challenges at the intersection of scientific research and its commercialization.

Over the years, Sten has been recognized for his significant contributions to the sector. He has served on various committees, including the Audit Committee at both Stipe Therapeutics and Orphazyme A/S, highlighting his expertise in governance and financial oversight. His involvement with the Danish Venture Capital and Private Equity Association (DVCA) exemplifies his dedication to advancing the venture capital industry in Denmark and supporting emerging enterprises.

Achievements

Sten Verland D. MSc's career is marked by a series of notable achievements that reflect his leadership and innovation in the life sciences arena. His role as CEO & co-owner at M&B A/S (now Taconic Biosciences) positioned him at the helm of a company that has made significant strides in animal models for biomedical research.

Moreover, his strategic vision was instrumental in the successful growth of Verland Capital, where he focused on investments in cutting-edge biotech firms. Sten's commitment to fostering innovation is further demonstrated through his active participation in various selection committees related to both funding and incubation of promising biotechnology projects, such as the InnoBooster and InnoFounder committees at Innovation Fund Denmark.

His hands-on experience in research, including positions at renowned institutions like the Department of Clinical Chemistry at Bispebjerg Hospital and the Department of Genetics at UC Berkeley, has also equipped him with the insights necessary for impactful decision-making. Sten's ability to build and guide high-performing teams in multicultural environments has been a key factor in his success across diverse organizations.

With a reputation for being an industry thought leader, Sten Verland has not only contributed to advancing scientific research and business practices but has also played an integral role in shaping the future of biotech investments in Denmark. His collaborative approach and unwavering dedication to innovation continue to inspire many in the life sciences sector.

Related Questions

How did Sten Verland develop his expertise in executive management and strategic development in the life sciences sector?
What are some of the most significant contributions Sten Verland has made during his tenure as General Partner at Sunstone Life Science Ventures?
In what ways did Sten Verland's educational background in Immunology and Mathematics influence his career trajectory in biotechnology entrepreneurship?
How has Sten Verland's role in various committees and boards shaped the landscape of venture capital in Denmark?
What leadership strategies has Sten Verland employed to successfully guide companies like Action Pharma A/S and Zymenex through their growth phases?
MSc Sten Verland
Add to my network

Location

Copenhagen, Capital Region, Denmark